Fluocinolone + Hydroquinone + Tretinoin

Generic Medicine Info
Indications and Dosage
Moderate to severe melasma of the face
Adult: As cream containing fluocinolone acetonide 0.01%, hydroquinone 4% and tretinoin 0.05%: Apply a thin layer onto the hyperpigmented areas of melasma once daily, 30 minutes before bedtime. Treatment duration should not exceed 8 wk.
Tuberculosis of skin, herpes (including varicella); sulfite allergy.
Special Precautions
Prolonged treatment with corticosteroids may increase the risk of Kaposi's sarcoma. Systemic absorption of topical corticosteroids may cause suppression of hypothalamic-pituitary-adrenal axis especially in younger children. Hydroquinone may cause gradual blue/black darkening of the skin. Safety and efficacy have not been established in children. Excessive bleaching may occur in patients with darker skin tone. Avoid UV exposure, including sunlight. Pregnancy and lactation.
Adverse Reactions
Erythema, pruritus, dry skin, burning sensation, desquamation. Acne, pigmentation change, irritation, papules, rash, rosacea, vesicles.
Drug Interactions
Avoid concurrent use with drugs that are photo-sensitising.
Food Interaction
Avoid excesive intake of vitamin A. Avoid concurrent admin with dong quai or St John's wort.
Description: Fluocinolone acetonide is a synthetic fluorinated corticosteroid that is used topically for its anti-inflammatory, anti-pruritic and vasoconstrictive properties. Hydroquinone is used as a depigmenting agent. Tretinoin is a retinoid that is appears to stimulate mitosis, increases turnover of follicular epithelial cells and reduces their cohesiveness.
Absorption: Topical application: Minimal.
Store at 20-25°C.
Disclaimer: This information is independently developed by MIMS based on Fluocinolone + Hydroquinone + Tretinoin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in